ForSight Robotics has expanded the first-in-human clinical experience of its JASPER Robotic Surgical Platform to 26 patients after completing another 14 fully robotic-assisted cataract procedures, moving the ophthalmic robotics developer beyond its initial proof that the technology could perform cataract surgery in humans. The privately held company reported that all 26 procedures were completed robotically without conversion to manual surgery and that patients followed conventional cataract anesthesia and same-day discharge protocols.
The August 6 update matters because the challenge confronting ForSight is beginning to change. Its April 2026 first-in-human announcement addressed a fundamental feasibility question: could a robotic system perform an entire cataract procedure in a human patient? The expanded experience starts addressing a different and commercially more consequential issue: can that technology operate without substantially disrupting the highly standardized, high-volume clinical workflow already used for cataract surgery?
That distinction also sets the limits of what has been demonstrated. ForSight has reported procedural completion and compatibility with routine anesthesia and outpatient discharge, but the latest disclosure does not provide comparative visual outcomes, procedure duration, complication rates, endothelial cell measurements, learning-curve data or a controlled comparison with manually performed cataract surgery. The 26-patient experience therefore represents an encouraging procedural feasibility and workflow signal, rather than evidence that robotic surgery produces superior clinical outcomes.
Why does completing all 26 cataract procedures robotically matter for JASPER’s development?
ForSight said every procedure in the 26-patient clinical experience was completed using JASPER without conversion to manual surgery. Patients received either topical anesthesia alone or mild sedation, and all were discharged on the day of surgery, practices broadly consistent with contemporary outpatient cataract care. The procedures form part of the company’s ongoing first-in-human study, with Alexey Rapoport performing the surgeries and Robert T. Ang of the Asian Eye Institute serving as principal investigator.
For an early surgical robotics programme, avoiding conversion is relevant because it tests whether the system can support the sequence of surgical tasks required rather than merely demonstrating isolated robotic movements. JASPER is designed around surgeon-controlled telemanipulation and incorporates bimanual robotic manipulation, three-dimensional visualization, real-time eye tracking, motion scaling, tremor reduction and computer vision. Importantly, describing the operations as fully robotic-assisted should not be interpreted as autonomous cataract surgery. The surgeon remains in control of the procedure through the system.
This is particularly significant in ophthalmology because cataract surgery is already highly optimized. A new robotic platform is not entering a field where the existing procedure is slow, poorly standardized or routinely dependent on general anesthesia. It is attempting to add robotics to a procedure that experienced ophthalmic teams can perform efficiently in an outpatient environment.
JASPER therefore has to meet a higher practical bar than simply showing that robotic surgery is technically possible. It must eventually demonstrate that whatever benefits the platform provides in precision, consistency, ergonomics, training or access are sufficient to justify the additional equipment, support infrastructure and purchasing decisions associated with a surgical robot.
Has ForSight shown that robotic cataract surgery improves patient outcomes?
Not yet, based on the information released with this latest clinical update.
The company reported successful robotic completion of the procedures and compatibility with standard clinical workflow, but those measures should not be confused with comparative evidence of improved safety, visual acuity, refractive accuracy or postoperative recovery. No head-to-head comparison with conventional cataract surgery was presented in the August 6 announcement. Nor did the company disclose detailed adverse-event data or longer-term follow-up outcomes across the 26 patients.
That does not diminish the technological significance of performing the procedure robotically. It instead defines where JASPER currently sits on the evidence curve. An early first-in-human programme typically needs to establish feasibility and generate information that can shape larger clinical studies. Claims around standardization, reduced surgical variability or better outcomes will require data designed specifically to test those questions.
Procedure time will be another important metric. Cataract surgery is commonly performed at high volumes, making operating-room throughput economically important for hospitals and ambulatory surgical centres. Even a technologically impressive system could encounter adoption resistance if robotic setup, docking or intraoperative workflow materially increases the time required per case without demonstrating a corresponding clinical or operational advantage.
ForSight has now shown that its system can operate within familiar anesthesia and discharge practices. Demonstrating comparable or better throughput while maintaining acceptable clinical performance would represent another level of validation.
Why is routine workflow integration becoming the decisive commercial question?
Workflow is particularly important in surgical robotics because the technology competes for more than clinical attention. It competes for operating-room space, capital budgets, staff time, surgeon training and hospital engineering support.
ForSight said the latest procedures used the same general anesthesia approach followed in routine cataract practice, namely topical anesthesia or mild sedation rather than requiring general anesthesia, while patients followed same-day outpatient care. Principal investigator Robert T. Ang indicated that the system complemented the existing cataract workflow rather than requiring the clinical pathway to be reconstructed around the robot.
That is commercially meaningful, although it remains early evidence.
Hospitals evaluating JASPER will eventually need far more detailed information. Procurement teams will want to understand acquisition costs, installation requirements, instrument compatibility, service arrangements, maintenance schedules, staff training, operating-room footprint and potentially any recurring per-procedure costs.
Surgeons will have another set of questions. How quickly can an experienced cataract surgeon become proficient with telemanipulation? Does robotic control preserve or improve procedural efficiency? What happens when a difficult case requires rapid adaptation? How easily can a surgical team convert to conventional instruments if necessary?
These implementation questions often determine whether sophisticated surgical technology moves from technically successful demonstrations into repeatable commercial use.
Could JASPER address the enormous global gap in access to cataract surgery?
The scale of cataract disease creates an unusually large potential use case for ophthalmic robotics. The World Health Organization estimates that cataract affects more than 94 million people globally and says roughly one in two people who need cataract surgery still lack access to it. The World Health Assembly has established a target of increasing effective cataract surgery coverage by 30 percentage points by 2030.
ForSight has positioned JASPER partly around this access problem. The company argues that robotic precision, standardized execution and eventually more intelligent surgical capabilities could help expand the availability of ophthalmic surgery in a world facing uneven distribution of trained eye-care specialists.
The clinical need is real. Whether robotics becomes a practical solution to that need is considerably less established.
The regions with the largest cataract treatment gaps frequently face broader constraints including limited surgical infrastructure, shortages of trained personnel, affordability pressures and uneven access to specialist care. The World Health Organization has identified workforce shortages, cost, waiting times and access barriers as continuing obstacles to cataract surgery coverage.
A sophisticated robotic platform would therefore need an economic and operational model capable of functioning in environments where healthcare resources may already be constrained. Reliability, servicing, instrument supply, technical support and surgeon availability could be as important as robotic precision.
The access argument may eventually become one of JASPER’s strongest commercial narratives, but clinical scale and healthcare-system economics will have to support it.
What is the regulatory status of the JASPER robotic cataract surgery platform?
JASPER remains an investigational technology under development. ForSight Robotics states that the platform has not been cleared by the United States Food and Drug Administration and is not commercially available in the United States. The company’s latest announcement similarly states that JASPER has not yet been approved for commercial use.
ForSight has said it intends to progress through further clinical studies and regulatory submissions, but the company has not publicly established in this announcement the eventual United States regulatory pathway or a specific commercial launch timetable.
That distinction matters because completing first-in-human procedures is a clinical development milestone, not marketing authorization.
ForSight did secure ISO 13485:2016 certification in February 2025 for its medical-device quality management system, an important organizational step as a developer prepares clinical and regulatory programmes. ISO certification, however, should not be interpreted as authorization to market JASPER.
The platform was previously known as ORYOM before being renamed JASPER. The company introduced the JASPER name by the time it announced its first fully robot-assisted human cataract surgery in April 2026.
Can ForSight Robotics finance the expensive path from clinical robotics to commercialization?
ForSight entered its human clinical programme with substantial venture backing. The company raised $125 million in a Series B financing announced in June 2025, bringing reported funding at that time to approximately $195 million. Eclipse led the round, with participation from investors including an undisclosed strategic investor, Fred Moll, Adani Group and Reiya Ventures.
That financing is significant because surgical robotics requires capital well beyond basic product development. Clinical studies, manufacturing systems, regulatory submissions, surgeon training infrastructure, service organizations and commercial installations can consume substantial resources before a platform reaches meaningful procedure volumes.
ForSight’s capital base gives it greater room to pursue those steps, but funding does not remove the adoption challenge. Surgical robots become commercially valuable when hospitals use them repeatedly, not merely when systems are installed.
The business model will therefore eventually come into sharper focus. Investors and prospective customers will want to know how ForSight intends to price JASPER, whether instruments generate recurring revenue, what procedure volumes are required to justify a purchase and how the economics compare with conventional cataract surgery equipment.
None of those questions is answered by the 26-patient milestone, but they become increasingly important as the technology moves closer to regulatory submissions.
What should clinicians and hospitals watch after ForSight’s 26-patient milestone?
The next phase should provide evidence that moves beyond technical completion.
Larger clinical experience will need to establish the consistency of JASPER across surgeons, patients and operating environments. Detailed safety reporting, visual outcomes, refractive accuracy, procedural duration and any conversions or device-related complications will help determine whether the system’s engineering capabilities translate into measurable clinical or workflow value.
For hospitals, the strongest eventual adoption case may not depend on one benefit alone. A combination of predictable surgical performance, reduced surgeon physical burden, reproducibility, useful digital data and acceptable procedure economics could prove more persuasive than a narrow claim around robotic precision.
ForSight is also positioning robotics as infrastructure for future AI-enabled surgical capabilities. That is a longer-term technology strategy rather than an established clinical capability. JASPER today remains surgeon-controlled, and future artificial intelligence functions would need their own validation and regulatory scrutiny depending on their intended role.
The 26-patient milestone nevertheless moves ForSight beyond the novelty of a single first-in-human operation. Repeated robotic completion using familiar anesthesia and outpatient care suggests that the company is beginning to test whether robotic ophthalmic surgery can coexist with the workflow that made cataract surgery one of medicine’s highest-volume procedures.
That is an important progression, but it is also where the harder questions begin. ForSight now needs to show that JASPER can deliver consistent clinical performance across a larger population, satisfy regulators and offer hospitals a sufficiently compelling operational and economic case. If those pieces come together, the opportunity extends well beyond demonstrating that a robot can perform cataract surgery. The real test is whether ophthalmic robotics can become practical enough to be used every day.